Subscribe

February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Immunotherapy with PD-1 Inhibitors the Newest Break­­through in Hodgkin Lymphoma
Wayne Kuznar
Read More
Leukemia
Psychological Distress and Financial Burden Impact Adherence to CML Treatment
Phoebe Starr
Read More
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Kate Smith
Read More
Emerging Therapies
The Hematology Pipeline Is Abundant
Wayne Kuznar, Kate Smith
Read More
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Kate Smith
Read More
Financial Toxicity Impacts Treatment Adherence
Kate Smith
Read More
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Kate Smith
Read More
High Cancer Drug Prices Hurt Patients
Read More
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
Read More
Economic Value of Survival Gains for MDS Could Exceed $100 Billion
Chase Doyle
Read More
Page 1 of 3
Results 1 - 10 of 26
Copyright © Engage Healthcare Communications, LLC. All rights reserved.